Medical Education
B.Sc.: University of Toronto, Toronto, Canada, 1989
M.Sc.: Physiology, University of Toronto, Toronto, Canada, 1991
Ph.D.: University of Toronto, Toronto, Canada, 1996
Medical Degree: University of Toronto, Toronto, Canada, 1997
Residency: Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 2000
Fellowship: Clinical, Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medicial School, Boston, Massachusetts, 2003
Fellowship: Research, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, 2003
Honors and Awards
Listed in Best Doctors in America, 2007-2013 (Best Doctors, Inc.)
Award of Excellence - Internal Medicine, Partners HealthCare, Harvard, Boston, 2003
Wightman Award for Internal Medicine, Faculty of Medicine, University of Toronto, 1997
Disclosure of Financial Interests with IndustryWashington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.
Dr. Simon Fisher reported the following earned financial interests during calendar year 2011. Move your mouse over a header for more info.
| Company | Royalties Royalties: When a faculty member invents or conceives a new or improved process or product, the company that manufactures the product will make royalty payments to the faculty member. Royalty payments usually are a small percentage of the company’s revenue related to that product. | Consulting &
Advisory Boards Consulting and Advisory Boards: Faculty may be paid to provide expertise to a company by being their consultant, or by serving on an advisory board. | Speaker Fees Speaker Fees: Companies may pay faculty to speak to professional audiences about their products. |
| Merck | | | $10,001-$25,000 |
To learn more about Washington University's policies on collaborations with industry,
click here.
Books and Book Chapters
Fisher SJ, Kahn CR. Physiological Mechanisms in Homeostatic Control of Glucose. In: Clinical Endocrinology, 3rd Ed. (Eds. M Besser and M Thorner) by Harcourt Publishers Limited, 2002
Shi ZQ, Fisher SJ, Giacca A, Efendic S, van de Werve G and Vranic M. Are Some of the Adaptive Effects of Hyperglycemia Beneficial in Diabetes? In: Glucose Fluxes, Exercise and Diabetes. (Eds. R Kawamori, M Vranic, ES Horton, M Kubota) by Smith-Gordon, Great Britain, pp 117-123, 1995
Fisher SJ, Shi ZQ, Lekas M, Giacca A and Vranic M. Role of hyperglycemia in regulating glucose uptake by the diabetic muscle during exercise. In: Diabetes 1995
Marliss EB, Sigal RJ, Fisher SJ, Manzon A, Halter JB and Vranic M. Glucoregulation in Intense Exercise and Its Implications For Persons with Diabetes Mellitus. In: Glucose Fulxes, Exercise and Diabetes. (eds. R Kawamori, M Vranic, ES Horton, M Kubota) by Smith-Gordon, Great Britian, pp 55-66, 1995
Selected Journal Articles
Fisher SJ and Kahn CR. Insulin signalling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest, 2003
Norris A, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear L, Gonzalez FJ, Spiegelman BM and Kahn CR. Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112:608-618
Fisher SJ, Shi ZQ, Lickley HL, Efendic S, Vranic M and Giacca A. Low dose insulin-like growth factor-I has no selective advantage over insulin in regulating glucose metabolism in hyperglycemic depancreatized dogs. J Endocrinology 2001; 168:49-58
Sigal RJ, Fisher SJ, Halter JB, Vranic M and Marliss EB. Glucoregulation during and after intense exercise: Effects of b-adrenergic blockade in subjects with Type 1 diabetes mellitus. J Clin Endo Matb 1999; 84:3961-3971
For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Simon J. Fisher